Benjamin J. Zeskind - 03 Feb 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Issuer symbol: IMRX
Transactions as of: 03 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Feb 2026, 08:10:18 UTC
Previous filing: 03 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Zeskind Benjamin J.	PRESIDENT AND CEO, Director	245 MAIN STREET, SECOND FLOOR, CAMBRIDGE	/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind	05 Feb 2026	0001870062

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMRX	Stock Option	Award	$0	+688,000		$0.000000	688,000	03 Feb 2026	Class A Common Stock	688,000	$4.91	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.